nabu.science
MethodologyAboutContact

 

Reliability concern: This paper was retracted on 2024-01-09. See notice: 10.1155/2024/9814185.

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-55673A92·Framework v5.0·Pipeline v0.4·Evaluated 01 Jun 2026·OECD: 3.2 Clinical medicine·Subfield: Radiology, Nuclear Medicine and Imaging·Basis: Full text·Type: Observational cohort study

Magnetic Resonance Imaging Features in Diagnosis of Breast Cancer and Evaluation of Effect of Epidermal Growth Factor Receptor-Targeted Therapy.

Yang et al.Yang, Zhang·2022·BioMed research international·10.1155/2022/3127058 ↗

In brief

A single-centre breast cancer imaging study whose segmentation conclusions contradict its own metrics and whose treatment claims lack the randomisation they assert.

ReliabilityConcerns4 of 4 checks completeRead the 3 entries ↓
Abstract

Breast cancer diagnosis and treatment are important healthcare issues in the Industrialized World. In this study, magnetic resonance imaging (MRI) images are used to diagnose breast cancer (BC) and analyze the application effect of epidermal factor receptor-targeted therapy in the treatment of BC. A total of 858 patients diagnosed with BC in Jincheng People's Hospital from 2019 to 2021 are included and randomly divided into an experimental group and a control group. The experimental group is treated with epidermal growth factor receptor- (EGFR-) targeted therapy, and the control group is treated with conventional chemotherapy according to subsequent treatment modalities. Experimental results show that compared with manual segmentation, machine automatic segmentation includes the local and edge information of the image with higher accuracy, compared with benign and malignant tumors. There are significant differences in the changes of Tpeak, SSmax, El, E2, and E5, P < 0.05, with SSmax and El having the greatest changes. After chemotherapy, the recorded maximum diameter of cancer foci in the control and the experimental groups are 26.4 ± 11.6 mm and 20.3 ± 13.5 mm, respectively, and the difference is statistically meaningful (P < 0.05). The ADC value (12.74 ± 2.08) in the experimental group is higher than that (9.7 ± 1.88) in the control group (P < 0.05). There is a significant difference in SSmax between the control group and experimental group (P < 0.05), the SImax, pH values of the control group are significantly higher than those of the experimental group (P < 0.05), and the SSmaxR value (7.82 ± 6.24) in the experimental group is lower than that in the control group (10.08 ± 6.25), but the difference is not significant, P > 0.05. The proposed MRI method has high sensitivity and accuracy in the diagnosis of BC, improving the detection rate of lesions, compared with conventional chemotherapy. In addition, epidermal factor receptor-targeted therapy has a better therapeutic effect, with significant changes in cancer foci, which has the value of clinical promotion.

Strengths · Limitations

Strengths

#contribution

Moderately large single-centre clinical cohort

The study includes 858 patients with pathological confirmation, providing a reasonable sample for a single-centre investigation of both MRI diagnostic parameters and treatment response monitoring.

↳ Section 2.1

#methodological rigour

Detailed MRI parameter reporting across multiple measures

The paper reports multiple quantitative MRI outcomes (TIC parameters, semiquantitative measures, ADC values, tumour diameter changes) with explicit numerical results for both diagnostic differentiation and treatment response, following established breast MRI methodology.

↳ Sections 2.3, 3.2–3.5

#methodological rigour

ROC analysis with diagnostic cut-offs for treatment monitoring

The paper provides ROC curves with area-under-curve values, cut-off points, sensitivity, and specificity for multiple MRI-derived parameters (ΔD%, ΔADC%, ΔSImax%, ΔpH%) as treatment response indicators.

↳ Sections 3.3–3.5, Figures 8, 10, 13

Limitations

#reporting

Segmentation conclusion contradicts reported metrics

The paper concludes machine segmentation has 'higher accuracy' than manual segmentation, but 4 of 5 reported evaluation metrics (RVD: 6.82% vs 4.63%; VOE: 10.27% vs 6.36%; ASSD: 1.47mm vs 0.98mm; MSSD: 3.88mm vs 1.85mm) show manual segmentation performing better. Only RMS favours machine segmentation.

↳ Section 3.1, Discussion paragraph 1

#methodological rigour

Treatment comparison lacks randomisation and confounding control

Despite claiming patients were 'randomly divided,' the methods describe allocation based on 'subsequent treatment modalities.' No randomisation procedure, allocation concealment, baseline characteristics comparison (beyond tumour size), or confounding adjustment strategy is described, yet the paper draws causal conclusions about EGFR-targeted therapy superiority.

↳ Sections 2.1, 3.3–3.5, Discussion, Conclusions

#methodological rigour

Unspecified treatment protocol limits interpretability

The EGFR-targeted agent is never named, the dose, duration, and line of therapy are not described, and patient selection criteria for EGFR therapy (e.g., EGFR expression status, breast cancer subtype) are not reported. This makes the therapeutic findings uninterpretable and non-replicable.

↳ Section 2.1, Discussion

Does this match your read? Add your assessment ↓

Withdrawn — shown for reference only

Nabu Commentary

This paper presents a single-centre observational study of 858 breast cancer patients that attempts to address both MRI diagnostic utility and EGFR-targeted therapy efficacy. The scores reflect converging evidence of fundamental methodological problems: treatment allocation is described as 'random' but was based on clinical treatment modality assignment, with no confounding control applied to the therapeutic comparison. The segmentation analysis contains a direct results-interpretation inversion, with the paper's conclusion of 'higher accuracy' contradicted by 4 of 5 reported metrics. Impact potential scores are constrained by the unspecified treatment protocol — the EGFR agent is never named, making the therapeutic findings non-replicable and non-actionable. The quality score of 2.07 reflects that while the clinical questions are relevant and the sample size is reasonable, the execution cannot support the clinical recommendations made in the conclusions.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.1±0.2

Contribution
2.1

The paper addresses two distinct clinical questions (MRI diagnostic utility and EGFR-targeted therapy comparison) but neither advances substantially beyond existing literature. The MRI diagnostic component replicates established findings, while the therapeutic comparison lacks agent specification, treatment protocol detail, and survival outcomes needed for a meaningful clinical contribution.

Introduction; Conclusions — 'has the value of clinical promotion'

epidermal factor receptor-targeted therapy has a better therapeutic effect...which has the value of clinical promotion

Methodological Rigour
1.9

Fundamental design and execution deficiencies undermine the core claims: the paper asserts 'random division' but describes allocation by treatment modality with no randomisation procedure, no baseline characteristics comparison beyond tumour size, no confounding control, and causal claims from observational data. ADC values are reported without units, the EGFR agent is never specified, and statistical methods are limited to t-tests and chi-squared tests with no adjustment for confounding.

Section 2.1 (allocation), Section 2.6 (statistics), Section 3.4 (ADC without units), Discussion (causal language)

randomly divided into an experimental group and a control group...according to subsequent treatment modalities

Reporting
2.6

The paper follows conventional section structure and is readable at a surface level, but interpretive clarity is compromised by misleading language ('randomly divided' for non-random allocation), a segmentation conclusion that contradicts the reported metrics, and blending of three distinct research aims without clear delineation.

Section 3.1 (segmentation interpretation), Section 2.1 ('randomly divided'), Abstract

machine automatic segmentation...with high precision

Positioning
2.2

The introduction provides general epidemiological and imaging background, but the paper does not engage with the most relevant prior literature on EGFR-targeted therapy by breast cancer subtype or position its findings against existing RCT evidence. The limitations section acknowledges only 'time and personal ability' constraints without addressing the major methodological limitations.

Introduction; Section 5 (Conclusions/limitations); Discussion

limited by time and personal ability, there are still many shortcomings

Reliability

Concerns4 of 4 checks


Internal CoherenceConcern

Multiple internal contradictions are present: the segmentation accuracy conclusion contradicts 4 of 5 reported metrics, the paper claims 'random division' but describes treatment allocation by clinical modality, parameter counts in benign/malignant data are inconsistent with parameter labels, and the SSmax directional interpretation in the Discussion contradicts the Results section data.

Research ConductNoted

Ethics approval is declared but no approval number is provided. Informed consent is stated. No conflict of interest statement, no trial registration, and no power calculation are present. Data availability is claimed upon reasonable request with no repository or persistent identifier.

Flags: 2 declared / 5 total

Reference IntegrityClean

All 30 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordConcern

This paper was retracted on 2024-01-09. See notice: 10.1155/2024/9814185.

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Breast cancer
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
BeneficiariesLarge
CitationsFWCI 0.1
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The claim rests on one single-centre comparative clinical study of 858 patients with no independent, multi-site, or confirmatory replication.

From the paper
“epidermal factor receptor-targeted therapy had a better therapeutic effect, with significant changes in cancer foci, which has the value of clinical promotion.”

The paper states its findings merit promotion into clinical practice, naming the clinical setting and purpose for which clinicians would apply them.

Pathway

Oncologists and radiologists would use MRI semi-quantitative parameters to diagnose breast cancer and monitor EGFR-targeted therapy response in routine clinics.

Barrier

The single-centre design and subject-dependent MRI parameters mean the findings still require independent confirmation before clinical adoption.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. How Does Diagnostic Accuracy Evolve with Increased Breast MRI Experience?

    Wu, Alikhassi, Curpen · 2023 · Clinical medicine

    Primary claim

    Diagnostic accuracy improved exponentially with increased MRI experience (definition B, OR of 1.27 and 1.61 for 5 and 10 years, respectively, p = 0.03 for both).

    Tentative
    Evidence Score
    2.3±0.1
    Reliability
    Caveats
  2. General cognitive function and the brain's structural connectome

    Buchanan, Moodie, Batziou, et al. · 2026 · Basic medicine

    Primary claim

    g is supported by a widely distributed white matter network whose macroscopic wiring capacity, microstructural organisation, and age sensitivity contribute in distinct ways.

    Tentative
    Evidence Score
    3.6±0.2
    Reliability
    Caveats
  3. The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network

    Markiewicz, Thompson, Wardlaw, et al. · 2026 · Clinical medicine

    Primary claim

    CL values across 74 scans showed excellent test-retest agreement (ICC = 0.968), improving to 0.987 after exclusion of one attenuation correction related outlier.

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats

How the rubric works →